A nanocell that can work like a smart bomb for cancer treatment is to be reported in Nature by MIT. The nanocell will work by penetrating into the tumor, seal the opening and then deliver the lethal dose of anti-cancer toxins like a 'stealth bimb'. This will leave the healthy cells unharmed.
The experiments currently done on mice cancer like melanoma and lung cancer have the potential of being a revolutionary form of drug delivery mechanism in cancers. The drugs that can kill cancer cells are available however they cannot be given in a high dose due to their side effects. However the double-acting, drug-packing "nanocell" can prove to be effective and safe and prolong survival of cancers.
AdvertisementThis study reported in the July 28 issue of Nature has the following discussion:
"We brought together three elements: cancer biology, pharmacology and engineering," said Ram Sasisekharan, a professor in MIT's Biological Engineering Division and leader of the research team.
"The fundamental challenges in cancer chemotherapy are its toxicity to healthy cells and drug resistance by cancer cells," Sasisekharan said. "So cancer researchers were excited about anti-angiogenesis," the theory that cutting off the blood supply can starve tumors to death. That strategy can backfire, however, because it also starves tumor cells of oxygen, prompting them to create new blood vessels and instigate metastasis and other self-survival activities.
The next obvious solution would be combining chemotherapy and anti-angiogenesis-dropping the bombs while cutting the supply lines. But combination therapy confronted an inherent engineering problem. "You can't deliver chemotherapy to tumors if you have destroyed the vessels that take it there," Sasisekharan said. Also, the two drugs behave differently and are delivered on different schedules: anti-angiogenics over a prolonged period and chemotherapy in cycles.
"We designed the nanocell keeping these practical problems in mind," he said. Using ready-made drugs and materials, "we created a balloon within a balloon, resembling an actual cell," explains Shiladitya Sengupta, a postdoctoral associate in Sasisekharan's laboratory.
In addition to Sasisekharan and Sengupta, the co-authors are David Eavarone, Ishan Capila and Ganlin Zhao of MIT's Biological Engineering Division; Nicki Watson of the Whitehead Institute for Biomedical Research; and Tanyel Kiziltepe of MIT's Department of Chemistry.
The team loaded the outer membrane of the nanocell with an anti-angiogenic drug and the inner balloon with chemotherapy agents. A "stealth" surface chemistry allows the nanocells to evade the immune system, while their size ( 200 nanometers ) makes them preferentially taken into the tumor. They are small enough to pass through tumor vessels, but too large for the pores of normal vessels.
Once the nanocell is inside the tumor, its outer membrane disintegrates, rapidly deploying the. The blood vessels feeding the tumor then collapse, trapping the loaded nanoparticle in the tumor, where it slowly releases the chemotherapy.
The team tested this model in mice. The double-loaded nanocell shrank the tumor, stopped angiogenesis and avoided systemic toxicity much better than other treatment and delivery variations.
But it is patient survival and quality of life that really inspire this research, Sasisekharan said. Eighty percent of the nanocell mice survived beyond 65 days, while mice treated with the best current therapy survived 30 days. Untreated animals died at 20.
"It's an elegant technique for attacking the two compartments of a tumor, its vascular system and the cancer cells," said Judah Folkman of Children's Hospital Boston. "This is a very neat approach to drug delivery," said MIT Institute Professor Robert Langer.
The nanocell worked better against melanoma than lung cancer, indicating the need to tweak the design for different cancers. "This model enables us to rationally and systematically evaluate drug combinations and loading mechanisms," says Sasisekharan. "It's not going to stop here. We want to build on this concept."
Elizabeth A. Thomson
Assistant Director, Science & Engineering News
Massachusetts Institute of Technology
News Office, Room 11-400
77 Massachusetts Ave.
Cambridge, MA 02139-4307
617-258-5402 ( ph ); 617-258-8762 ( fax )
Further Information on Chemotherapy from Medindia
Chemotherapy is defined as the treatment of cancer using chemical substances as anticancer or chemotherapy drugs to stop or destroy the multiplication of cancer cells. Alimta (pemetrexed) is a new drug recently approved by the Food and Drug Administration (FDA) for use with Cisplatin in the treatment of patients with malignant pleural mesothelioma. Alimta blocks the enzymes necessary for DNA copying and cell division and the drug is supplemented with Vitamin B12 and Folic acid to minimize the side effects of skin rash and other effects.
You May Also Like